Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hacker

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Cancer Immunology, Immunotherapy : CII|July 27, 2005
Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicityUlrich T Hacker, Ines Schildhauer, Margarita Céspedes Barroso, et al.
Medicine and Science in Sports and Exercise|January 27, 2000
Intravenous versus oral rehydration during a brief period: responses to subsequent exercise in the heatD J Casa, C M Maresh, L E Armstrong, et al.
ESMO Gastrointestinal Oncology|April 30, 2026
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)G Stocker, U T Hacker, R Lordick Obermannová, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2023
Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12CMyriam Boeschen, Christina Katharina Kuhn, Hubert Wirtz, et al.
Medicine and Science in Sports and Exercise|June 19, 2001
Perceptual responses in the heat after brief intravenous versus oral rehydrationC M Maresh, J A Herrera-Soto, L E Armstrong, et al.
British Journal of Cancer|August 22, 2013
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205T Hoehler, G von Wichert, C Schimanski, et al.
Frontiers in Oncology|November 9, 2023
Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study)Andrea Alberti, Gertraud Stocker, Florian Lordick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib studyB Schultheis, G Folprecht, J Kuhlmann, et al.
British Journal of Cancer|February 1, 2017
A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix depositionL M Schiffmann, M Brunold, M Liwschitz, et al.
Molecular Therapy. Methods & Clinical Development|September 11, 2023
Modifying immune responses to adeno-associated virus vectors by capsid engineeringMartin Bentler, Romain Hardet, Moritz Ertelt, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Cancer Immunology, Immunotherapy : CII|July 27, 2005
Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicityUlrich T Hacker, Ines Schildhauer, Margarita Céspedes Barroso, et al.
Medicine and Science in Sports and Exercise|January 27, 2000
Intravenous versus oral rehydration during a brief period: responses to subsequent exercise in the heatD J Casa, C M Maresh, L E Armstrong, et al.
ESMO Gastrointestinal Oncology|April 30, 2026
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)G Stocker, U T Hacker, R Lordick Obermannová, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2023
Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12CMyriam Boeschen, Christina Katharina Kuhn, Hubert Wirtz, et al.
Medicine and Science in Sports and Exercise|June 19, 2001
Perceptual responses in the heat after brief intravenous versus oral rehydrationC M Maresh, J A Herrera-Soto, L E Armstrong, et al.
British Journal of Cancer|August 22, 2013
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205T Hoehler, G von Wichert, C Schimanski, et al.
Frontiers in Oncology|November 9, 2023
Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study)Andrea Alberti, Gertraud Stocker, Florian Lordick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib studyB Schultheis, G Folprecht, J Kuhlmann, et al.
British Journal of Cancer|February 1, 2017
A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix depositionL M Schiffmann, M Brunold, M Liwschitz, et al.
Molecular Therapy. Methods & Clinical Development|September 11, 2023
Modifying immune responses to adeno-associated virus vectors by capsid engineeringMartin Bentler, Romain Hardet, Moritz Ertelt, et al.
Pageof 7